FDA Approves ROMIDEPSIN — Zydus Lifesciences Limited
Zydus Lifesciences Limited announced the FDA approval of Romidepsin for the treatment of cutaneous T-cell lymphoma. This regulatory green light is expected to bolster the company's portfolio and intensify competition in the oncology generic market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed